Genentech, a member of the Roche Group RHHBY,
today announced positive results from two Phase II studies that
evaluated the investigational cancer immunotherapy atezolizumab
(anti-PDL1; MPDL3280A) in people with advanced non-small cell lung
cancer (NSCLC). In the randomized Phase II study, POPLAR, atezolizumab
met its primary endpoint and showed a statistically significant survival
benefit compared to chemotherapy (HR=0.54; p=0.014) in people
with recurrent NSCLC whose tumors expressed medium and high levels of
PD-L1, which corresponded with people living 7.7 months longer than
people who received docetaxel chemotherapy. A separate, single-arm Phase
II study, BIRCH, met its primary endpoint and showed that atezolizumab
shrank tumors (objective response rate, ORR) in up to 27 percent
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in